5.1 Passive targeting

Passive targeting in nanobiotechnology leverages the enhanced permeability and retention effect to deliver nanoparticles to tumors. This approach exploits the leaky vasculature and poor lymphatic drainage of tumors, allowing nanoparticles to accumulate without specific targeting ligands.

Key factors influencing passive targeting include nanoparticle size, shape, and surface charge. The optimal size range is 10-200 nm, with neutral or slightly negative surface charge preferred. Passive targeting offers reduced systemic toxicity and improved drug bioavailability compared to conventional therapies.

Principles of passive targeting

• Passive targeting relies on the enhanced permeability and retention (EPR) effect, which is the tendency of nanoparticles to accumulate in tumor tissue due to its unique pathophysiological characteristics
• Exploits the differences in vasculature between normal and tumor tissues, allowing nanoparticles to preferentially accumulate in tumors without the need for specific targeting ligands
• Enables the delivery of therapeutic agents to tumor sites while minimizing exposure to healthy tissues, potentially reducing side effects and improving treatment efficacy

Factors influencing passive targeting

Size of nanoparticles

Top images from around the web for Size of nanoparticles

• 

  Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine ... View original

  Is this image relevant?

• 

  Frontiers | Tumor Exosome Mimicking Nanoparticles for Tumor Combinatorial Chemo-Photothermal Therapy View original

  Is this image relevant?

• 

  Frontiers | Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS ... View original

  Is this image relevant?

• 

  Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine ... View original

  Is this image relevant?

• 

  Frontiers | Tumor Exosome Mimicking Nanoparticles for Tumor Combinatorial Chemo-Photothermal Therapy View original

  Is this image relevant?

1 of 3

Top images from around the web for Size of nanoparticles

• 

  Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine ... View original

  Is this image relevant?

• 

  Frontiers | Tumor Exosome Mimicking Nanoparticles for Tumor Combinatorial Chemo-Photothermal Therapy View original

  Is this image relevant?

• 

  Frontiers | Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS ... View original

  Is this image relevant?

• 

  Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine ... View original

  Is this image relevant?

• 

  Frontiers | Tumor Exosome Mimicking Nanoparticles for Tumor Combinatorial Chemo-Photothermal Therapy View original

  Is this image relevant?

1 of 3

• Nanoparticle size plays a crucial role in passive targeting, as it determines the ability to extravasate through the leaky tumor vasculature and avoid rapid renal clearance
• Optimal size range for passive targeting is typically between 10-200 nm, allowing nanoparticles to exploit the EPR effect effectively
  • Nanoparticles smaller than 10 nm are rapidly cleared by the kidneys
  • Nanoparticles larger than 200 nm may have difficulty penetrating the tumor tissue

Shape of nanoparticles

• Shape influences the circulation time, cellular uptake, and tumor penetration of nanoparticles
• Spherical nanoparticles are most commonly used due to their ease of synthesis and favorable pharmacokinetic properties
• Non-spherical shapes (rods, discs) have shown enhanced cellular uptake and tumor penetration in some studies, but their clinical applications are still being explored

Surface charge of nanoparticles

• Surface charge affects the interaction of nanoparticles with blood components and cell membranes
• Neutral or slightly negative surface charge is preferred for passive targeting, as it minimizes non-specific interactions and prolongs circulation time
  • Positively charged nanoparticles tend to bind non-specifically to cells and proteins, leading to rapid clearance
• Surface modification with hydrophilic polymers (PEG) can help shield the surface charge and improve the stealth properties of nanoparticles

Enhanced permeability and retention (EPR) effect

Tumor vasculature vs normal vasculature

• Tumor vasculature is characterized by abnormal structure and function, with wide fenestrations (gaps) between endothelial cells and poor lymphatic drainage
• Normal vasculature has tight junctions between endothelial cells, preventing the extravasation of large molecules and nanoparticles
• The leaky tumor vasculature allows nanoparticles to selectively accumulate in tumor tissue, while the poor lymphatic drainage helps retain them in the tumor microenvironment

Accumulation of nanoparticles in tumors

• Nanoparticles in the optimal size range (10-200 nm) can extravasate through the leaky tumor vasculature and accumulate in the tumor interstitial space
• The poor lymphatic drainage in tumors prevents the efficient removal of nanoparticles, leading to their prolonged retention in the tumor tissue
• The EPR effect is more pronounced in rapidly growing tumors with extensive angiogenesis, such as many solid tumors (breast, lung, colon)

Advantages of passive targeting

Reduced systemic toxicity

• Passive targeting minimizes the exposure of healthy tissues to therapeutic agents, as nanoparticles preferentially accumulate in tumor tissue
• Lower systemic drug concentrations lead to reduced side effects compared to conventional chemotherapy, which often causes widespread toxicity
• The EPR effect allows for the use of higher drug doses while maintaining a favorable safety profile

Improved drug bioavailability

• Encapsulation of drugs in nanoparticles protects them from premature degradation and elimination, increasing their circulation time and bioavailability
• The prolonged retention of nanoparticles in tumor tissue allows for sustained drug release, maintaining therapeutic concentrations at the target site
• Improved bioavailability can lead to enhanced treatment efficacy and reduced dosing frequency

Limitations of passive targeting

Lack of specificity

• Passive targeting relies on the EPR effect, which is not entirely tumor-specific, as some normal tissues (liver, spleen) also have fenestrated vasculature
• Nanoparticles can accumulate in these organs, potentially causing off-target effects and toxicity
• The lack of active targeting ligands may limit the cellular uptake and intracellular delivery of therapeutic agents

Variability in EPR effect

• The magnitude of the EPR effect can vary significantly between different tumor types, stages, and even individual patients
• Factors such as tumor size, location, and vascularity can influence the extent of nanoparticle accumulation
• The heterogeneity of the EPR effect makes it challenging to predict the efficacy of passively targeted nanomedicines in a given patient or tumor

Nanoparticle design for passive targeting

Optimal size range

• Nanoparticles should be designed within the optimal size range (10-200 nm) to maximize the EPR effect and tumor accumulation
• Size can be controlled through the choice of materials, synthesis methods, and post-synthesis modifications
• Monodisperse nanoparticle populations with narrow size distributions are preferred for consistent behavior and reproducible results

Favorable surface properties

• Surface properties should be engineered to minimize non-specific interactions and prolong circulation time
• Hydrophilic polymers (PEG) can be used to create a stealth coating, reducing protein adsorption and immune recognition
• Neutral or slightly negative surface charge is desirable to avoid non-specific cellular uptake and rapid clearance

Stealth nanoparticles

• Stealth nanoparticles are designed to evade the mononuclear phagocyte system (MPS) and prolong circulation time
• PEGylation is the most common strategy for creating stealth nanoparticles, as the hydrophilic PEG chains form a protective layer around the nanoparticle surface
• Other strategies include the use of biomimetic coatings (cell membranes) or zwitterionic materials to minimize protein adsorption and immune recognition

Applications of passive targeting

Cancer drug delivery

• Passive targeting is widely used for the delivery of chemotherapeutic agents, such as doxorubicin, paclitaxel, and cisplatin
• Nanoparticle formulations (liposomes, polymeric nanoparticles) can encapsulate these drugs, improving their solubility, stability, and pharmacokinetics
• Examples of FDA-approved passively targeted nanomedicines for cancer treatment include Doxil (liposomal doxorubicin) and Abraxane (albumin-bound paclitaxel)

Imaging and diagnostics

• Passive targeting can be used to deliver contrast agents or imaging probes to tumor sites for enhanced visualization and diagnosis
• Nanoparticles can be loaded with fluorescent dyes, magnetic resonance imaging (MRI) contrast agents, or radionuclides for various imaging modalities
• Examples include iron oxide nanoparticles for MRI, quantum dots for fluorescence imaging, and gold nanoparticles for computed tomography (CT) imaging

Passive targeting in clinical trials

Current progress

• Several passively targeted nanomedicines have been approved for clinical use, demonstrating the potential of this approach in cancer therapy
• Numerous clinical trials are ongoing to evaluate the safety and efficacy of novel passively targeted nanoparticle formulations
• Combination therapies using passively targeted nanoparticles with other treatment modalities (radiotherapy, immunotherapy) are being explored

Challenges and future directions

• Improving the understanding of the factors influencing the EPR effect and developing strategies to predict and optimize tumor accumulation
• Addressing the heterogeneity of the EPR effect through patient stratification and personalized medicine approaches
• Developing multifunctional nanoparticles that combine passive targeting with active targeting, stimuli-responsive drug release, or imaging capabilities
• Investigating the long-term safety and potential toxicity of passively targeted nanomedicines, especially with regard to nanoparticle accumulation in off-target organs
• Optimizing the scale-up and manufacturing processes for the reproducible and cost-effective production of passively targeted nanomedicines